RT @CCR_AACR: Phase 3 Study (CheckMate 214): Treatment-free survival over 42 months in advanced renal cell carcinoma. https://t.co/VJ6zB4ex…
20 followers
766 followers
RT @DrMeredithGT: ⬆️ Treatment-free survival (TFS) w/ NIVO+IPI vs sunitinib *without* ⬆️ toxicity in #CheckMate214 @OncoAlert
34,025 followers
RT @DrMeredithGT: ⬆️ Treatment-free survival (TFS) w/ NIVO+IPI vs sunitinib *without* ⬆️ toxicity in #CheckMate214 @OncoAlert
4,225 followers
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial https://t.co/5a7ZPoARln